Daraxonrasib shrinks pancreatic tumors and targets multiple RAS proteins
NewsBytes | May 9, 2026 2:39 PM CST
FDA awards daraxonrasib National Priority Voucher
The side effects so far have been mild to moderate, like skin rash or feeling tired, and no life-threatening side-effects popped up during testing.
Because of these strong results, the US Food and Drug Administration included daraxonrasib in the first group to receive National Priority Voucher status.
While final approval is still pending, patients with few other options can already access it through expanded access programs.
READ NEXT
-
TVK-AIADMK Deal Nears Closure? Who All Did CM Vijay Meet Ahead Of the Floor Test
-
#MeToo-Era Rape Case Returns To Court As Hollywood Producer Harvey Weinstein Faces Third Trial Over Actor Jessica Mann Allegations
-
'I Don't Trust Pakistan': US Senator Graham Blasts Islamabad Over Role Shielding Iranian Military Jets As Iran War Costs Hit $29 Billion
-
'We’ll Finish The Job': Trump Vows US Will Win Iran War 'Peacefully or Otherwise', Claims Blockade 100% Effective
-
CBI Takes Over NEET 2026 Paper Leak Probe As 150 Candidates Questioned Across 3 States
